Lenalidomide ( /lɛnəˈlɪdɵmaɪd/), initially known as CC-5013 and marketed as Revlimid by Celgene, is a derivative of thalidomide introduced in 2004.
It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide and bortezomib are considered therapeutic breakthroughs in the treatment of myeloma, which generally carries a poor prognosis.
This text uses material from Wikipedia, licensed under CC BY-SA
Sorry, no news articles match your request
About
Phys.org™ is a leading web-based science, research and technology news service which covers a full range of topics.
Phys.org is a part of Science X network. With a global reach of over 10 million monthly readers and featuring dedicated websites for science (Phys.org), technology (Tech Xplore) and medical research (Medical Xpress), the Science X network is one of the largest online communities for science-minded people.
Read moreIdentify the news topics you want to see and prioritize an order.
Science never stops. Get notified about trending stories.